{"id":4095,"date":"2026-11-05T02:00:00","date_gmt":"2026-11-05T06:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4095"},"modified":"2026-11-05T20:35:26","modified_gmt":"2026-11-06T00:35:26","slug":"iks03-shows-early-activity-in-relapsed-b-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4095","title":{"rendered":"IKS03 Shows Early Activity in Relapsed B Cell Lymphoma"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Iksuda Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Phase 1 dose-escalation data<\/p>\n

Modality<\/strong><\/p>\n

Antibody-drug conjugate (prodrug PBD payload)<\/p>\n

Asset<\/strong><\/p>\n

IKS03<\/p>\n

Target<\/strong><\/p>\n

CD19<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed or refractory B-cell non-Hodgkin lymphoma<\/p>\n

Summary<\/h4>\n

Iksuda disclosed first Phase 1 dose-escalation data for CD19-directed prodrug ADC IKS03 on November 5. Nine of 17 efficacy-evaluable relapsed or refractory B-cell lymphoma patients responded, but heterogeneous histologies, an evaluability restriction and small cohorts prevent a comparative efficacy or safety conclusion.<\/p>\n

At a July 8 cutoff, 21 patients had received IKS03 across five dose levels; 17 completed two cycles in the first four levels and met the sponsor-defined efficacy-evaluable set. Nine responded, including five complete metabolic responses. Three of four prior CAR-T recipients responded. Seven of 21 had treatment-related adverse events, including one grade 4 and two grade 3 neutropenia events. The maximum tolerated dose was not reached. Updated data are scheduled for ASH in December.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> a tumor-activated pyrrolobenzodiazepine prodrug payload could preserve activity after CD19 CAR-T with manageable systemic exposure. Responses in heavily treated patients and preliminary tolerability support dose expansion. Counterargument: the post-CAR subgroup is four patients, response duration is immature, and cross-study safety comparisons are invalid.<\/p>\n

Interpretation B:<\/strong> response patterns may reflect indolent histology and patient selection, while aggressive Richter-transformed disease appears harder to treat. Five of eight nonresponders had Richter-transformed lymphoma, but numbers are too small for subtype inference. A disease-specific expansion with all-treated denominators, response duration, cytopenias, infection and dose intensity would test the claim.<\/p>\n

Company and Product Background<\/h4>\n

Iksuda develops antibody-drug conjugates. IKS03 binds CD19 on malignant B cells and delivers a tumor-activated prodrug pyrrolobenzodiazepine payload intended to damage DNA after cellular uptake. The Phase 1 trial enrolls multiple relapsed or refractory B-cell non-Hodgkin lymphoma subtypes.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Numerical clinical data were newly disclosed ahead of the conference; the December poster is future follow-up.<\/li>\n
  • The 53% response uses 17 evaluable patients, not 21 treated.<\/li>\n
  • Company language claiming a leading therapeutic index is unproven against contemporary ADCs, bispecifics and CAR-T.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    IKS03 earns further study as a post-CAR-T option, especially if response durability and cytopenia profile hold in larger defined lymphoma cohorts. Current evidence cannot rank it against alternatives.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: cautiously positive for observed response; uncertain for comparative benefit-risk. Confidence in Facts: moderate for company-reported numbers and trial design. Confidence in Interpretation: low because of sample size and histologic heterogeneity.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Iksuda disclosed first Phase 1 dose-escalation data for CD19-directed prodrug ADC IKS03 on November 5. Nine of 17 efficacy-evaluable relapsed or refractory B-cell lymphoma patients responded, but heterogeneous histologies, an evaluability restriction and small…<\/p>\n","protected":false},"author":1,"featured_media":4107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[726,1382,1381],"class_list":["post-4095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-b-cell-lymphoma","tag-iks03","tag-iksuda-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4095"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4095\/revisions"}],"predecessor-version":[{"id":4117,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4095\/revisions\/4117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4107"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}